Pic: John M Lund Photography (DigitalVision) via Getty Images.
Check up: Rhinomed (ASX:RNO) soars with NSW COVID contract, and genetic testing fails to impress
Health & Biotech
share
It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining.
Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with NSW Health Pathology for one million SARS-CoV-2 Rhinoswabs as part of the department’s program to support testing capability.
The Rhinoswab technology aims to improve the sample collection process, and with extensive testing, was proven to be substantially more comfortable and easier to use than the standard nasal swab, while capturing a larger sample.
“The Rhinoswab can make a meaningful impact on the SARS-CoV-2 testing process and enable more people to be tested quickly and easily,” Rhinomed CEO Michael Johnson said.
“With approximately 2 billion SARS-CoV-2 tests having been carried out globally over the last 18 months, there is a major opportunity for Rhinoswab to radically improve the testing process, clinical outcomes and user experience.”
The next cab off the ranks was Respiri Limited (ASX:RSH) which rose a respectable 55% on nothing but a presentation detailing its commercialisation plans for its wheezo asthma management wheeze-detecting device and app.
Dimerix (ASX:DXB) was up 36% after securing $20 million in funding for pivotal Phase 3 trials for the company’s proprietary DMX-200 formula in the treatment of FSGS kidney disease.
And up 25% was Neuren Pharmaceuticals (ASX:NEU) after announcing it has completed Phase 3 enrolment for the study of trofinetide in Rett syndrome (neuro-development disorder), with results on track to be published in Q4 of 2021.
Nova EYE Medical (ASX:EYE) was up 21% on no news, and Telix Pharmaceutical (ASX:TLX) jumped 15% on the news that London-based Great Ormond Street Hospital has received a UK research ethics approval to commence a Phase II academic study of Telix’s investigational product, TLX66 (90Y-DTPA-besilesomab) for use in children with high-risk leukemia.
Here’s a table showing how ASX-listed healthcare stocks have been performing.
| Code | Company | Price | %Yr | %Wk | MktCap |
|---|---|---|---|---|---|
| RNO | Rhinomed Ltd | 0.37 | 357 | 85 | $ 92,640,333.18 |
| RSH | Respiri Limited | 0.099 | -32 | 52 | $ 71,561,238.21 |
| DXB | Dimerix Ltd | 0.305 | -47 | 36 | $ 66,329,764.50 |
| NEU | Neuren Pharmaceut. | 2.3 | 80 | 25 | $ 271,621,215.96 |
| EYE | Nova EYE Medical Ltd | 0.44 | 47 | 21 | $ 62,503,470.03 |
| TLX | Telix Pharmaceutical | 6.12 | 352 | 15 | $ 1,774,227,470.40 |
| CBL | Control Bionics | 0.745 | 15 | $ 35,426,326.85 | |
| PXS | Pharmaxis Ltd | 0.11 | 0 | 15 | $ 54,350,899.68 |
| CTE | Cryosite Limited | 0.455 | 168 | 14 | $ 21,086,803.35 |
| PTX | Prescient Ltd | 0.1975 | 213 | 13 | $ 131,728,811.44 |
| IBX | Imagion Biosys Ltd | 0.078 | -8 | 11 | $ 81,327,864.46 |
| AMT | Allegra Orthopaedics | 0.25 | 0 | 11 | $ 26,114,800.75 |
| 1AD | Adalta Limited | 0.09 | -18 | 10 | $ 21,085,443.71 |
| SDI | SDI Limited | 0.97 | 45 | 9 | $ 116,488,219.40 |
| EXL | Elixinol Wellness | 0.125 | -26 | 9 | $ 39,382,894.25 |
| ATX | Amplia Therapeutics | 0.2 | 33 | 8 | $ 24,340,161.30 |
| CPH | Creso Pharma Ltd | 0.135 | 200 | 8 | $ 161,536,137.57 |
| BD1 | Bard1 Life Sciences | 1.425 | 53 | 8 | $ 128,768,483.73 |
| MDR | Medadvisor Limited | 0.36 | -25 | 7 | $ 139,631,716.66 |
| BNO | Bionomics Limited | 0.1925 | 135 | 7 | $ 196,481,365.08 |
| IMU | Imugene Limited | 0.2975 | 431 | 6 | $ 1,591,994,197.80 |
| CYP | Cynata Therapeutics | 0.51 | -24 | 6 | $ 71,638,297.00 |
| CYC | Cyclopharm Limited | 1.68 | 14 | 6 | $ 158,270,324.99 |
| IPD | Impedimed Limited | 0.105 | 31 | 6 | $ 156,885,907.40 |
| MDC | Medlab Clinical Ltd | 0.18 | 24 | 6 | $ 61,591,620.78 |
| IHL | Incannex Healthcare | 0.28 | 383 | 6 | $ 293,878,839.93 |
| VLS | Vita Life Sciences.. | 1.13 | 60 | 6 | $ 57,917,873.20 |
| HCT | Holista CollTech Ltd | 0.064 | -3 | 5 | $ 17,346,992.48 |
| GSS | Genetic Signatures | 1.32 | -43 | 4 | $ 192,924,782.10 |
| MMJ | MMJ Group Hlds Ltd | 0.081 | -16 | 4 | $ 17,936,410.83 |
| ACW | Actinogen Medical | 0.086 | 282 | 4 | $ 144,468,593.59 |
| NXS | Next Science Limited | 1.49 | 7 | 3 | $ 296,960,863.50 |
| EPN | Epsilon Healthcare | 0.155 | -40 | 3 | $ 29,869,577.10 |
| OPT | Opthea Limited | 1.28 | -46 | 3 | $ 465,079,691.83 |
| PAL | Palla Pharma Ltd | 0.36 | -56 | 3 | $ 59,907,870.31 |
| PAB | Patrys Limited | 0.039 | 227 | 3 | $ 70,964,279.30 |
| TD1 | Tali Digital Limited | 0.046 | 64 | 2 | $ 42,867,666.29 |
| AGH | Althea Group | 0.29 | -17 | 2 | $ 73,464,591.20 |
| OSX | Osteopore Limited | 0.38 | -38 | 1 | $ 31,215,120.00 |
| CAJ | Capitol Health | 0.385 | 83 | 1 | $ 400,958,029.68 |
| BOT | Botanix Pharma Ltd | 0.079 | 52 | 1 | $ 74,931,939.70 |
| KZA | Kazia Therapeutics | 1.245 | 55 | 1 | $ 163,039,217.07 |
| AC8 | Auscann Grp Hlgs Ltd | 0.098 | -35 | 1 | $ 43,614,163.89 |
| PBP | Probiotec Limited | 2.15 | 6 | 1 | $ 167,911,688.84 |
| LDX | Lumos Diagnostics | 1.26 | 1 | $ 185,438,230.06 | |
| SOM | SomnoMed Limited | 2.35 | 82 | 0 | $ 195,311,983.40 |
| SCU | Stemcell United Ltd | 0.016 | 33 | 0 | $ 16,693,130.53 |
| RHT | Resonance Health | 0.135 | -7 | 0 | $ 62,215,017.44 |
| ONT | 1300 Smiles Limited | 7.08 | 10 | 0 | $ 167,642,958.72 |
| NSB | Neuroscientific | 0.29 | 26 | 0 | $ 42,324,134.69 |
| MEB | Medibio Limited | 0.0075 | -38 | 0 | $ 12,565,430.49 |
| M7T | Mach7 Tech Limited | 0.99 | 5 | 0 | $ 241,227,670.32 |
| LCT | Living Cell Tech. | 0.012 | -14 | 0 | $ 6,857,291.77 |
| JHC | Japara Healthcare Lt | 1.38 | 191 | 0 | $ 368,801,312.64 |
| IVX | Invion Ltd | 0.013 | 30 | 0 | $ 72,014,049.84 |
| IMC | Immuron Limited | 0.16 | -56 | 0 | $ 36,359,455.36 |
| IDT | IDT Australia Ltd | 0.38 | 124 | 0 | $ 92,346,165.45 |
| ICS | ICSGlobal Limited | 0.575313 | 16 | 0 | $ 6,054,604.94 |
| ICR | Intelicare Holdings | 0.14 | -60 | 0 | $ 6,573,088.34 |
| GTG | Genetic Technologies | 0.007 | -30 | 0 | $ 73,808,721.14 |
| BXN | Bioxyne Ltd | 0.03 | 150 | 0 | $ 19,204,361.94 |
| ALT | Analytica Limited | 0.002 | 0 | 0 | $ 9,227,602.26 |
| AHK | Ark Mines Limited | 0.034 | 0 | 0 | $ 1,778,919.95 |
| ADR | Adherium Ltd | 0.016 | -36 | 0 | $ 34,065,375.36 |
| ACR | Acrux Limited | 0.13 | -24 | 0 | $ 36,829,701.22 |
| 1ST | 1St Group Ltd | 0.019 | -44 | 0 | $ 8,492,338.06 |
| PSQ | Pacific Smiles Grp | 2.33 | 55 | 0 | $ 382,996,651.20 |
| ARX | Aroa Biosurgery | 1.08 | -23 | 0 | $ 372,147,210.31 |
| MVF | Monash IVF Group Ltd | 0.93 | 66 | -1 | $ 364,308,575.40 |
| BWX | BWX Limited | 5.02 | 25 | -1 | $ 729,145,275.84 |
| PNV | Polynovo Limited | 2.19 | -2 | -1 | $ 1,474,895,338.12 |
| LBT | LBT Innovations | 0.099 | -27 | -1 | $ 28,622,401.24 |
| RGS | Regeneus Ltd | 0.083 | -41 | -1 | $ 25,193,684.13 |
| MVP | Medical Developments | 4.13 | -35 | -1 | $ 301,449,562.56 |
| ALC | Alcidion Group Ltd | 0.355 | 154 | -1 | $ 377,304,858.72 |
| ILA | Island Pharma | 0.345 | -1 | $ 15,030,108.10 | |
| FFC | Farmaforce Ltd | 0.066 | 27 | -1 | $ 8,624,944.68 |
| CHM | Chimeric Therapeutic | 0.32 | -2 | $ 64,954,993.95 | |
| MEM | Memphasys Ltd | 0.062 | -60 | -2 | $ 47,167,980.56 |
| NYR | Nyrada Inc. | 0.295 | 48 | -2 | $ 35,641,825.63 |
| BIT | Biotron Limited | 0.057 | -43 | -2 | $ 40,712,097.35 |
| PCK | Painchek Ltd | 0.056 | -49 | -2 | $ 60,847,459.15 |
| UBI | Universal Biosensors | 0.78 | 179 | -2 | $ 136,812,457.32 |
| PGC | Paragon Care Limited | 0.255 | 50 | -2 | $ 87,850,175.92 |
| PAA | Pharmaust Limited | 0.092 | -53 | -2 | $ 29,139,152.64 |
| VHT | Volpara Health Tech | 1.085 | -17 | -2 | $ 280,216,315.32 |
| MXC | Mgc Pharmaceuticals | 0.04 | 60 | -2 | $ 95,724,793.01 |
| LSH | Lifespot Health Ltd | 0.095 | 172 | -3 | $ 16,341,294.83 |
| CAN | Cann Group Ltd | 0.305 | -38 | -3 | $ 91,624,527.02 |
| AHC | Austco Healthcare | 0.145 | 93 | -3 | $ 41,207,397.90 |
| PAR | Paradigm Bio. | 1.835 | -36 | -3 | $ 427,190,762.52 |
| OSP | Osprey Med Inc | 0.0135 | -63 | -4 | $ 33,355,143.61 |
| CDY | Cellmid Limited | 0.051 | -50 | -4 | $ 9,558,958.56 |
| CDX | Cardiex Limited | 0.066 | 25 | -4 | $ 60,192,480.08 |
| RCE | Recce Pharmaceutical | 0.87 | -32 | -4 | $ 152,924,505.36 |
| ZLD | Zelira Therapeutics | 0.041 | -23 | -5 | $ 48,803,241.61 |
| EZZ | EZZ Life Science | 0.405 | -5 | $ 4,860,000.00 | |
| NC6 | Nanollose Limited | 0.1 | 108 | -5 | $ 14,571,264.06 |
| TRU | Truscreen | 0.058 | -5 | $ 23,223,440.19 | |
| CGS | Cogstate Ltd | 1.6 | 146 | -5 | $ 287,260,396.08 |
| NOX | Noxopharm Limited | 0.55 | 69 | -5 | $ 167,172,468.52 |
| ONE | Oneview Healthcare | 0.355 | 607 | -5 | $ 158,141,817.35 |
| AT1 | Atomo Diagnostics | 0.2175 | -42 | -5 | $ 89,911,874.14 |
| OSL | Oncosil Medical | 0.05 | -52 | -6 | $ 40,664,507.99 |
| SUD | Suda Pharmaceuticals | 0.049 | 26 | -6 | $ 24,521,819.29 |
| SHG | Singular Health | 0.245 | -6 | $ 16,820,305.32 | |
| BPH | BPH Energy Ltd | 0.065 | 225 | -6 | $ 43,219,760.29 |
| ATH | Alterity Therap Ltd | 0.032 | -45 | -6 | $ 77,019,986.50 |
| ZNO | Zoono Group Ltd | 0.605 | -74 | -6 | $ 100,718,751.27 |
| PYC | PYC Therapeutics | 0.15 | 31 | -6 | $ 493,043,545.97 |
| HXL | Hexima | 0.225 | -26 | -6 | $ 27,083,792.03 |
| OIL | Optiscan Imaging | 0.215 | 306 | -7 | $ 132,635,779.43 |
| PIQ | Proteomics Int Lab | 1.055 | 61 | -7 | $ 112,623,786.25 |
| RHY | Rhythm Biosciences | 0.905 | 725 | -7 | $ 185,054,917.07 |
| OCC | Orthocell Limited | 0.505 | 44 | -7 | $ 100,102,834.65 |
| CMP | Compumedics Limited | 0.44 | -6 | -7 | $ 82,380,770.82 |
| ADO | Anteotech Ltd | 0.185 | 243 | -8 | $ 364,514,142.46 |
| VBS | Vectus Biosystems | 1.19 | 40 | -8 | $ 37,669,918.86 |
| NTI | Neurotech Intl | 0.047 | 370 | -8 | $ 33,447,318.05 |
| JTL | Jayex Technology Ltd | 0.023 | -23 | -8 | $ 5,070,436.92 |
| DVL | Dorsavi Ltd | 0.023 | 5 | -8 | $ 8,071,449.16 |
| RAP | Resapp Health Ltd | 0.043 | -70 | -9 | $ 37,804,671.39 |
| OVN | Oventus Medical Ltd | 0.096 | -64 | -9 | $ 23,930,926.97 |
| IMM | Immutep Ltd | 0.465 | 158 | -9 | $ 404,188,330.48 |
| APH | AP Hemp Ltd | 0.31 | 121 | -9 | $ 24,833,293.88 |
| 4DX | 4Dmedical Limited | 1.535 | -8 | -9 | $ 315,523,202.13 |
| DOC | Doctor Care Anywhere | 0.725 | -9 | $ 132,762,459.46 | |
| S66 | Star Combo | 0.32 | -3 | -10 | $ 43,107,990.08 |
| VTI | Vision Tech, Inc | 1 | -38 | -10 | $ 24,344,565.00 |
| BDX | Bcaldiagnostics | 0.16 | -11 | $ 21,044,249.92 | |
| AVE | Avecho Biotech Ltd | 0.016 | 100 | -11 | $ 27,541,747.89 |
| RAC | Race Oncology Ltd | 2.93 | 233 | -12 | $ 440,422,571.15 |
| GLH | Global Health Ltd | 0.45 | 67 | -14 | $ 26,869,669.38 |
| ANP | Antisense Therapeut. | 0.17 | 113 | -15 | $ 94,788,596.60 |
| MX1 | Micro-X Limited | 0.235 | 42 | -18 | $ 119,522,452.40 |
Flat this fortnight was Genetic Technologies (ASX:GTG) despite completing the acquisition of EasyDNA for US$4 million in cash and scrip on 13 August – which currently sells paternity, oncology and health & wellness genomics-based laboratory tests through agreements with 12 laboratories in North America, AsiaPac and Europe.
“The strong alignment of this brand and platform with GTG’s planned expansion into ‘health and wellness’ testing was critical to our decision to acquire the business of EasyDNA and will deliver solid revenue growth and expansion in the future,” GTG CEO Simon Morriss said.
And Aroa Biosurgery (ASX:ARX) joined the flat pack, even with the announcement that a new retrospective study of real-world data in the International Wound Journal showing significantly improved wound closure times for diabetic foot ulcers and much greater probability of wound closure in wounds treated with its Endoform Natural – compared to wounds treated with a traditional collagen dressing.
Who’s the biggest loser?
Micro-X Limited (ASX:MX1) was the biggest loser, down 18%, followed by Antisense Therapeutics (ASX:ANP) down 15% – both on no news.
Dropping 14% was Global Health (ASX:GLH) despite announcing a new non-executive, independent director in Karen Corry and a new chief financial officer in Ershad Ali.
Race Oncology (ASX:RAC) dropped 12% after announcing that the first patient was dosed in the Phase 1b/2 trial in relapsed/refractory acute myeloid leukaemia at the Chaim Sheba Medical Centre in Israel.
At Stockhead, we tell it like it is. While Dimerix and Respiri are Stockhead advertisers, they did not sponsor this article.
